Paratek
Developing new treatment options for complex medical issues and providing new technologies to defeat superbugs.
Market cap
$128m
Enterprise value
$345m
Share price
$2.23 PRTK
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
$60.0m | Post IPO Debt | ||
| Total Funding | 000k | ||
Abingworth(exited)
Omega Funds(exited)
Aisling Capital(exited)
Pacific Growth Equities(exited)
IBT Management Corporation(exited)
D.E. Shaw Group(exited)
Hercules Capital(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 36 % | (3 %) | 163 % | 178 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (650 %) | (589 %) | (678 %) | (170 %) | (34 %) | (30 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (706 %) | (656 %) | (778 %) | (222 %) | (49 %) | (42 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 476 % | 336 % | 239 % | 55 % | 25 % | 25 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.